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Breast Cancer Screening: Early Detection Is Not Enough
Judy A. Tjoe, MD | Editorial
Surgical Breast Oncology, Aurora Health Care, Milwaukee, WI

I’ve never known a woman who looks forward to
getting her annual mammogram.
Nonetheless, uncomfortable and anxiety-provoking as
it can be, breast cancer screening is effective. While
lead time, length and healthy volunteer bias cannot
be ignored,1 numerous randomized controlled trials
and meta-analyses have consistently demonstrated
a reduction of 25–35% in breast cancer mortality
associated with routine screening mammography
among women age 50–74 years and a reduction of
10–18% among women age 40–49 years.2-7 A recently
published Canadian study following almost 2.8 million
women (85% of the country’s female population)
reported 40% less breast cancer-related mortality in
patients who participated in screening programs versus
those who did not (standardized mortality ratio = 0.60,
95% confidence interval 0.52–0.67). Interestingly, the
age at which a woman started screening did not greatly
affect the magnitude of this mortality reduction.8
Generally, screening is performed with the intent
of detecting cancer early and thereby increasing a
person’s chance of survival from the disease. Cancer
screening tests are selected based on their abilities
to test asymptomatic populations for disease on a
large scale at minimal cost. The test must have a
high detection rate of early-stage cancer in order to
enable intervention that can lessen future suffering or
mortality associated with the disease. In this issue of
Journal of Patient-Centered Research and Reviews,
two modes of breast cancer screening — radiographic
imaging and physical examination — are eloquently
reviewed and summarized for today’s practice.
Dr. Jennifer Lo astutely acknowledges that currently
there is insufficient evidence to state clinical breast
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exam is associated with any survival benefit; however,
it may serve, on an individualized basis, as an adjunct
to detect heretofore mammographically occult interval
cancers,9 which are more prevalent in women age
40–49 because of decreased mammographic sensitivity
attributable to greater breast density in 68% of cases.10
Dr. Summer Jatala and colleagues propose timing
and screening modalities specifically for women with
personal or family risk factors.11 Breast cancer screening
undergoes continuous and intense scrutiny and revision,
and recommendations based on a summary of current
literature are appreciated by the busy primary care
provider faced with constantly evolving data.
Of course, screening programs are only effective for
those women who choose to participate. It is important
to note that the patient must assume some responsibility
for her health and make the effort to attend the
clinical breast exam and/or screening mammography
appointment. This may sound simple, but, in fact, 33%
of women age ≥40 years who are eligible for screening
mammography do not participate, with the percentage
rising to 36% for Hispanic women. In 2010, 70% of
patients with no health insurance for more than 12
months did not undergo mammography12 in spite
of innumerable free screening programs offered
nationwide.
Unfortunately, the current state of breast cancer
screening, whether by clinical breast exam or
mammography, is fraught with drawbacks and
limitations.
Early detection comes at a price, both in time and
money. That premium is paid by the 1,339 women age
50–59 invited for screening before one breast cancer
death is prevented, a number that rises to 1,904 when
looking at women who start screening in their 40s.13
The expense is also shouldered by society as a whole,
which must find a way to pay for the approximately
50 million screening mammography exams per
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year, covering 70% of women in the United States at
an annual cost of $7.8 billion. The simulated cost of
annually screening 85% of women is reported to be
$10.1 billion, for which the largest driver of cost is
not the cost of mammography imaging, but rather the
frequency of screening and the percentage of women
screened.14 These simulation models do not even
consider the growing effect of newer and more expensive
screening and diagnostic technologies infiltrating
common practice (e.g. magnetic resonance imaging,
tomosynthesis and molecular imaging), which, to date,
have not been accompanied by data demonstrating
survival benefit. Furthermore, if the personal time
expended by women being screened is valuable, then
more than $1.5 billion can be added to annual screening
costs by applying the median U.S. hourly wage to an
estimated 2 hours allocated for traveling, waiting and
receiving screening-related examinations.15
Costs aside, screening also can lead to unintended
consequences such as false sense of security,
misdiagnosis and overdiagnosis. It is not uncommon
for a woman discovering she has breast cancer to feel
betrayed by years of normal mammograms. Annual
mammograms and clinical breast exams do not prevent
cancer; they simply detect disease after it has developed.
There is anxiety associated with each indeterminate
finding that requires additional diagnostic imaging
and biopsy to resolve. Approximately 1.6 million
breast biopsies are performed every year in the United
States,16 84% of which identify only a benign finding,
i.e. a false positive.17 The apprehension felt after a
false positive is discovered often extends beyond
work-up of the abnormality, well into future years of
screening mammography, even though the suspicious
finding was found to be benign. The possibility of a
false negative also exists, such as with invasive lobular
carcinoma presenting as a vague asymmetric density or
architectural distortion, a histological type notoriously
difficult to detect by screening mammography at early
stages.18
Perhaps the greatest tragedy of all is that once a breast
cancer is diagnosed, we have not yet discovered how
to avoid overtreatment by definitively differentiating
between malignancies that are programmed to
metastasize to vital organs and those “cancers”
that have little to no potential to metastasize. Of the
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261,000 breast cancers diagnosed in 2010, 54,000
were ductal carcinoma in situ (DCIS),17 a noninvasive
and thus non–life-threatening disease thought to be a
precursor of invasive carcinoma. But we do not know
if all DCIS are obligate precursors to invasive disease,
which ones are predestined to become an infiltrating
malignancy and within what time frame, or whether
the DCIS will eventually lead to life-threatening
distant metastases. Evidence suggests that death after
DCIS is quite rare. After 10-year follow-up of 2,123
patients diagnosed with pure DCIS and treated, Roses
and colleagues identified the rate of developing distant
breast cancer metastases to be only 0.14%.19
As necessary as regular screening is to detect earlystage breast cancer, clearly there is a critical need to
improve these tests.
What is missing from current screening outcomes is
the ability to differentiate invasive breast cancers
capable of distant metastasis that impact longevity
from those breast cancers that will lay dormant for 10,
20 or even 30+ years. In an autopsy series of women
not known to have had breast cancer during life, the
median prevalence of invasive breast cancer was 1.3%
and median prevalence of DCIS was 8.9%.20 Even
more powerful would be the ability to predict the
women originally diagnosed with high-risk markers
such as atypia or carcinoma in situ who will not go
on to develop an invasive malignancy. If this group
could be identified, the rising and concerning trend of
prophylactic mastectomies could be avoided. There is
much research interest in this particular field, and a few
promising predictive and prognostic genomic profiling
tests have been developed over the past decade.
In this era of tissue and serum biorepositories,
electronic medical records and emerging genetically
targeted cancer therapies, we may soon have the
capability to analyze the biological samples of women
with early noninvasive disease who subsequently
develop invasive cancer, identify distinguishing
biomolecular signatures from those samples and then
develop targeted therapies that abort the process of
carcinogenesis. Until then, our best hope for reducing
breast cancer-related suffering and mortality is early
detection through screening and continued research
supported by clinical trials.
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